Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

FDA
News

Fauci Boosted Johnson & Johnson Shots Give Comparable Protection To Moderna

-Dow Jones

byBenzinga Newsdesk

January 26, 2022

1 minute read

-Dow Jones

Janssen’s Darzalex Faspro Wins FDA Approval In Combination With Pomalidomide, Dexamethasone For Multiple Myeloma

By Vandana Singh

Today, 7:49 AM

The FDA has approved Janssen Biotech Inc’s, a unit of Johnson & Johnson (NYSE:JNJ) Darzalex Faspro (daratumumab and hyaluronidase-fihj) for multiple myeloma…

HALO

Redburn Partners Downgrades Atos to Neutral

By Benzinga Newsdesk

Today, 7:49 AM

Redburn Partners analyst Neil Steer downgrades Atos (OTC:AEXAY) from Buy to Neutral.

AEXAY

Psychedelic Treatments Vary Greatly By Cost And Setting, What About Efficacy?

By Andrew Ward

Today, 7:49 AM

Psychedelic therapy is on the rise. June 2022 data from Data Bridge Market Research reports that the US psychedelic drug market could be valued at $9.8 billion by 2029, with a nearly 17% CAGR.

GOOGL

Otter Tail Corporation Late Monday Reported Q2 EPS $2.05 Beat $1.39 Estimate, Sales $400.04M Beat $336.88M Estimate

By Bill Haddad

Today, 7:49 AM

Otter Tail (NASDAQ:OTTR) reported quarterly earnings of $2.05 per share which beat the analyst consensus estimate of $1.39 by 47.48 percent. This is a 102.97 percent increase over earnings of $1.01 per share from the

OTTR

Fauci Boosted Johnson & Johnson Shots Give Comparable Protection To Moderna

Related Posts

Janssen’s Darzalex Faspro Wins FDA Approval In Combination With Pomalidomide, Dexamethasone For Multiple Myeloma

Redburn Partners Downgrades Atos to Neutral

Psychedelic Treatments Vary Greatly By Cost And Setting, What About Efficacy?

Otter Tail Corporation Late Monday Reported Q2 EPS $2.05 Beat $1.39 Estimate, Sales $400.04M Beat $336.88M Estimate